SCHEMBL968994

SCHEMBL968994

CCCc1nc(C)c2c(Cl)nc3ccccc3n12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.51
MAPT P10636 4/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PDE4D Q08499 3/20 0.43
PDE3A Q14432 3/20 0.43
PDE2A O00408 2/20 0.43
PDE5A O76074 2/20 0.43
PDE4A P27815 2/20 0.43
PDE7A Q13946 2/20 0.43
PDE7B Q9NP56 2/20 0.43
PDE11A Q9HCR9 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 2/20 0.42
TYMS P04818 1/20 0.42
PDE6D O43924 1/20 0.41
PDE8A O60658 1/20 0.41
PDE9A O76083 1/20 0.41
PDE8B O95263 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971822 0.88 PDE10A (0.63) PDE10AMAPTLMNAHPGDSMN1; SMN2
SCHEMBL971457 0.83 TLR7 (0.52) PDE10AMAPTLMNAPDE4DPDE3A
SCHEMBL971026 0.82 PDE10A (0.46) PDE10APDE4DPDE3APDE2APDE5A
SCHEMBL8042597 0.80 PDE10A (0.49) PDE10APDE4DPDE3APDE2APDE5A
SCHEMBL972979 0.76 PDE10A (0.57) PDE10AMAPTHPGDSMN1; SMN2PDE4D
SCHEMBL7342631 0.76 TYMS (0.56) MAPTHPGDALDH1A1TYMSKMT2A
SCHEMBL8044666 0.73 PDE10A (0.81) PDE10APDE4DPDE3APDE2APDE5A
SCHEMBL4134084 0.72 PDE10A (0.65) PDE10APDE4DPDE3APDE2APDE5A
SCHEMBL970412 0.71 PDE10A (0.52) PDE10AMAPTHPGDSMN1; SMN2PDE4D
SCHEMBL14765127 0.71 PDE2A (0.53) PDE10APDE2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A PDE10A 3/4885MAPT 3499/4885LMNA 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.